Table 1: Complete Summary of Studies Design and Methodology – Table 1 continued: Complete Summary of Studies Design and Methodology – Table 1 continued: Complete Summary of Studies Design and Methodology – 1 continued: Complete Summary of Studies Design and Methodology – Table 1 continued: Complete Summary of Studies Design and Methodology – BD a day, CSR clinical study report, F female, ITTC intent-to-treat clinical population, M male, MRSA methicillin-resistant S. aureus, PK – – – – – – pharmacokinetic(s), SID infected dermatoses, SIRS skin infection rating scale, SITL, secondarily infected traumatic lesions, TID – –secondarily – – three times a day
Table 1: Complete Summary of Studies – Design and Methodology Table 1 continued: Complete Summary of Studies – Design and Methodology Table 1 continued: Complete Summary of Studies – Design and Methodology 1 continued: Complete Summary of Studies – Design and Methodology Table 1 continued: Complete Summary of Studies – Design and Methodology BD – a day, CSR – clinical study report, F – female, ITTC – intent-to-treat clinical population, M – male, MRSA – methicillin-resistant S. aureus, PK – pharmacokinetic(s), SID –secondarily infected dermatoses, SIRS – skin infection rating scale, SITL, secondarily infected traumatic lesions, TID – three times a day
auspar-retapamulin-131111-cer.docx